Profile data is unavailable for this security.
About the company
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
- Revenue in USD (TTM)312.30m
- Net income in USD-58.50m
- Incorporated2014
- Employees430.00
- LocationArvinas Inc5 Science ParkNEW HAVEN 06511-1966United StatesUSA
- Phone+1 (203) 535-1456
- Fax+1 (302) 636-5454
- Websitehttps://www.arvinas.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cullinan Therapeutics Inc | 0.00 | -216.81m | 684.69m | 111.00 | -- | 1.52 | -- | -- | -3.68 | -3.68 | 0.00 | 7.64 | 0.00 | -- | -- | 0.00 | -38.12 | -16.54 | -40.13 | -17.34 | -- | -- | -- | -1,797.10 | -- | -- | 0.00 | -- | -- | -- | -9.28 | -- | -- | -- |
| YD Bio Ltd | -100.00bn | -100.00bn | 693.93m | 5.00 | -- | 136.38 | -- | -- | -- | -- | -- | 0.0722 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.36 | -- | 0.0124 | -- | 45.76 | -- | -10,509.73 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 0.00 | -71.11m | 701.26m | 45.00 | -- | 2.90 | -- | -- | -1.14 | -1.14 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -28.80 | -35.63 | -30.41 | -38.94 | -- | -- | -- | -314.68 | -- | -- | 0.00 | -- | 2,752.05 | -- | 90.01 | -- | -20.09 | -- |
| Annexon Inc | 0.00 | -208.88m | 706.83m | 99.00 | -- | 3.49 | -- | -- | -1.39 | -1.39 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -68.11 | -42.65 | -76.07 | -45.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.95 | -- | -43.78 | -- |
| Kura Oncology Inc | 104.03m | -216.88m | 723.12m | 192.00 | -- | 2.98 | -- | 6.95 | -2.48 | -2.48 | 1.19 | 2.79 | 0.1844 | -- | -- | 541,817.70 | -38.45 | -26.38 | -44.88 | -28.06 | -- | -- | -208.48 | -1,266.72 | -- | -- | 0.0384 | -- | -- | -- | -13.99 | -- | -- | -- |
| Gyre Therapeutics Inc | 107.27m | 6.65m | 728.94m | 574.00 | 124.24 | 7.15 | 51.69 | 6.80 | 0.0646 | 0.0646 | 1.09 | 1.12 | 0.7537 | 0.6368 | 4.73 | 186,872.80 | 8.30 | -53.99 | 12.90 | -82.36 | 95.48 | 89.58 | 11.01 | -88.61 | 5.64 | -- | 0.00 | -- | -6.78 | -- | 113.00 | -- | 117.68 | -- |
| Personalis Inc | 69.10m | -73.88m | 729.08m | 229.00 | -- | 4.25 | -- | 10.55 | -0.8761 | -0.8761 | 0.8189 | 1.93 | 0.2863 | 7.71 | 4.96 | 301,759.80 | -30.61 | -29.82 | -36.03 | -34.69 | 26.67 | 28.44 | -106.92 | -105.71 | 4.69 | -- | 0.0133 | -- | 15.15 | 5.35 | 24.94 | -- | -28.17 | -- |
| Jade Biosciences Inc | 0.00 | -65.26m | 741.19m | 4.00 | -- | 2.73 | -- | -- | -11.45 | -11.45 | 0.00 | 5.50 | 0.00 | -- | -- | 0.00 | -44.48 | -47.29 | -50.06 | -50.63 | -- | -- | -- | -- | -- | -320.04 | 0.00 | -- | -- | -- | 7.80 | -- | -- | -- |
| Arvinas Inc | 312.30m | -58.50m | 748.21m | 430.00 | -- | 1.46 | -- | 2.40 | -0.8048 | -0.8048 | 4.30 | 7.97 | 0.3105 | -- | 22.63 | 726,279.10 | -5.82 | -20.58 | -7.36 | -25.05 | -- | -- | -18.73 | -211.50 | -- | -- | 0.0007 | -- | 235.54 | 43.71 | 45.85 | -- | -22.02 | -- |
| Kalvista Pharmaceuticals Inc | 15.12m | -210.31m | 753.65m | 270.00 | -- | 44.33 | -- | 49.85 | -3.95 | -3.95 | 0.2838 | 0.3363 | 0.0604 | -- | 1.51 | 55,992.59 | -84.00 | -49.86 | -97.02 | -54.21 | 87.95 | -- | -1,391.14 | -- | 7.21 | -82.77 | 0.9412 | -- | -- | -- | -44.85 | -- | 33.39 | -- |
| Maravai Lifesciences Holdings Inc | 192.28m | -121.24m | 756.89m | 550.00 | -- | 3.08 | -- | 3.94 | -0.8442 | -0.8442 | 1.34 | 0.961 | 0.1808 | 3.18 | 7.48 | 337,338.60 | -20.14 | 8.27 | -27.68 | 10.45 | 20.86 | 72.61 | -111.42 | 25.48 | 4.56 | -7.37 | 0.4288 | 0.00 | -10.30 | 12.61 | -21.69 | -- | 12.69 | -- |
| MiMedx Group Inc | 393.44m | 40.83m | 758.28m | 837.00 | 18.75 | 3.17 | 13.67 | 1.93 | 0.273 | 0.273 | 2.63 | 1.61 | 1.40 | 2.79 | 5.95 | 470,062.10 | 14.51 | 2.94 | 17.63 | 3.89 | 81.99 | 83.00 | 10.38 | 2.07 | 3.95 | -- | 0.0708 | -- | 8.52 | 3.12 | -24.73 | -- | -5.37 | -- |
| Arbutus Biopharma Corp | 14.61m | -42.28m | 765.45m | 44.00 | -- | 9.87 | -- | 52.41 | -0.2219 | -0.2219 | 0.0764 | 0.4032 | 0.1227 | -- | 11.62 | 331,954.50 | -35.50 | -44.03 | -39.50 | -49.46 | -- | -- | -289.45 | -433.59 | -- | -- | 0.0454 | -- | -65.98 | 0.5268 | 4.02 | -- | -20.93 | -- |
| Bicara Therapeutics Inc | 0.00 | -121.52m | 778.45m | 55.00 | -- | 1.93 | -- | -- | -5.03 | -5.03 | 0.00 | 7.38 | 0.00 | -- | -- | 0.00 | -25.61 | -- | -26.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.80 | -- | -- | -- |
| MapLight Therapeutics Inc | 0.00 | -92.43m | 781.32m | 109.00 | -- | -- | -- | -- | -2.23 | -2.23 | 0.00 | 1.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -39.26 | -- | -- | -- |
| Janux Therapeutics Inc | 10.00m | -101.90m | 790.34m | 74.00 | -- | 0.809 | -- | 79.03 | -1.67 | -1.67 | 0.1649 | 16.24 | 0.0116 | -- | -- | 135,135.10 | -11.85 | -13.75 | -12.17 | -14.23 | -- | -- | -1,018.95 | -743.21 | -- | -- | 0.00 | -- | 30.99 | -- | -18.36 | -- | -- | -- |
Data as of Feb 17 2026. Currency figures normalised to Arvinas Inc's reporting currency: US Dollar USD
43.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 6.74m | 10.49% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 5.48m | 8.54% |
| D. E. Shaw & Co. LPas of 06 Nov 2025 | 3.41m | 5.30% |
| Logos Global Management LPas of 13 Oct 2025 | 2.50m | 3.89% |
| Millennium Management LLCas of 30 Sep 2025 | 2.13m | 3.32% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.84m | 2.87% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.62m | 2.53% |
| Qube Research & Technologies Ltd.as of 30 Sep 2025 | 1.49m | 2.32% |
| Tang Capital Management LLCas of 30 Sep 2025 | 1.39m | 2.17% |
| Balyasny Asset Management LPas of 30 Sep 2025 | 1.21m | 1.88% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
